UCB is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology - UCB focuses on securing a leading position in severe disease categories.
Vision
To build a global biopharmaceutical leader, based on unique blending of innovation, entrepreneurship and proven experience bringing to specialists first, new medicines to treat patients suffering from severe diseases.
| Contact Details: |
| Alle de la Recherche, 60 |
| Brussels |
| |
| 1070 |
| Belgium |
| Tel: | +32/2/559.99.99 |
| Fax: | +32/2/559.99.00 |
| Email: | sally.miller@ucb-group.com |
| WWW: | ubc-group.com/
|
| |
Recent Publications by UCB S.A.: |  |
2,6-Quinolinyl derivatives as potent VLA-4 antagonists.
A new series of 2,6-quinolinyl derivatives was prepared leading to potent... | 25th April, 2007
| UCB S.A., R&D, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium.
| Bioorg Med Chem Lett. 2007 Jan 1;17(1):142-6. Epub 2006 Oct 10.
DOI Direct Link |
Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
High-throughput screening of the UCB sample collection identified the... | 25th April, 2007
| CNS Molecular and Cellular Biology, Centre for CNS Innovation, UCB S.A.,
| Bioorg Med Chem Lett. 2007 Jan 1;17(1):272-7. Epub 2006 Oct 5.
DOI Direct Link |
The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading depression in a rat neocortical slice model in vitro.
A protocol for inducing cortical spreading depression (SD) on rat... | 3rd February, 2007
| UCB S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.
| Brain Res Bull. 2006 Dec 11;71(1-3):23-8. Epub 2006 Aug 11.
DOI Direct Link |
Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
A specific binding site for the antiepileptic drug levetiracetam... | 26th July, 2006
| UCB S.A., CNS Research, Chemin du Foriest, 1420 Braine L'Alleud, Belgium.
| Eur J Pharmacol. 2006 Apr 24;536(1-2):102-8. Epub 2006 Mar 10.
DOI Direct Link |
Differential effects of cation-chloride co-transport-blocking diuretics in a rat hippocampal slice model of epilepsy.
The cation-Cl- co-transport-blocking loop diuretics have clinically known... | 13th July, 2006
| UCB S.A., CNS Research, B-1420 Braine-l'Alleud, Belgium.
| Epilepsy Res. 2006 May;69(2):93-9. Epub 2006 Feb 21.
DOI Direct Link |
→View more UCB S.A. research publications. |
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 594 times since April 2007, the link to the organisation's website has been followed 92 times
Recent Search Terms used to find this page: * UCB.com UK | UCB SA | ucb and patents | telephone ucb pharma alle de recherche | CNS Research Centre of UCB New Medicines home page | ucb braine chemin map | ucb braine l alleud | yahoo ucb sa | ucb cd40 | UCB pharmaceutics brain l alleud | .
Search for more companies in Brussels
Search for more companies in
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
UCB S.A.
